Furthermore, the analysis of databases for the expression of MAP17 in other types not sufficiently represented in our cohort, such as osteosarcoma or Ewing's sarcoma with a high MAP17 level, also shows a worse prognosis in either OS or metastasis-free survival (Supplementary Figure S3). This evidence concerns the gene PDZK1IP1 and osteosarcoma.